Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, announced today the appointment of Erin Quirk, M.D. as Chief Medical Officer (CMO). Dr. Quirk brings more than two decades of clinical medicine and drug development experience, most recently serving as Vice President of Clinical Research at Gilead Sciences. “Erin is a highly accomplished clinician with an extensive tr...